Reports Q4 revenue $19.7M, consensus $21.77M. Will Febbo, OptimizeRx CEO commented, "Macro headwinds made 2022 an extremely challenging year. As a result, we are taking a conservative approach to guidance for 2023. However, during 2022 we made the decision to skate to where the puck is going to be and strengthened our platform and team around advanced/smarter solutions, particularly our RWD-AI offering. We believe this is bearing fruit, which is best evidenced by our exiting 2022 with six RWD-AI deals. Even more encouraging is the RWD-AI pipeline that’s been built in recent months, which now encompasses several dozen deals. I believe our current revenue backlog, and the momentum we are currently seeing, positions the Company to return to at least double digit revenue growth this year."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx Announces Multi-Year Agreement with Top Hub Services Provider to Accelerate Access for Patients
- OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results
- OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET
- OptimizeRx’s Karina Castagna Named to MM+M’s 40 Under 40 List of the Medical Marketing Industry’s Brightest Young Stars
- OptimizeRx resumed with a Buy at B. Riley
